Medicines in the 21st century or pills, politics, potions, and profits: Where is public policy?

Drug Development Research

Volumn 59, Issue 3, 2003, Pages 269-291

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Drug discovery process; Health and inequality; Intellectual property; Medicines and public policy

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG INDUSTRY; ECONOMIC ASPECT; GENOMICS; HEALTH; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; MALARIA; MEDICINE; PILL; POLICY; POLITICS; PROFIT; PUBLIC HEALTH SERVICE; REVIEW; SANITATION; TUBERCULOSIS;

EID: 0041625711     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10282     Document Type: Review

References (271)

1. Abbott EA. Flatland. 1884. A romance in many dimensions. London: Seeley.
2. Abraham J. 2002 The pharmaceutical industry as a political player. Lancet 360:498-1502.
3. Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP. 2002. Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 20:36-42.
4. Adams SH. 1905. The great American fraud. Collier's Weekly Oct. 7. www.mtn.org/quack/ephemera/Oct7-01.htm
5. Adams DJ, Alewood PE, Crack DJ, Drinkwater RD, Lewis RJ. 1999. Conotoxins and their potential therapeutic application. Drug Dev Res 46:219-234.
6. Agres T. 2002. Life science patents enrich academe. Scientist Oct. 14.
7. AIDS Health Care Foundation. 2003. Trimeris, Roche set record $20,000 price for annual supply of Fuzeon. March 21. www.aidshealth.org/NewsRoom/news/N032103.htm
8. Aldhous P. 2003. The world's forgotten crisis. Nature 422:251-253.
9. ALLHAT. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981-2997.
10. Angell M. 2000. The pharmaceutical industry: to whom is it accountable? N Engl J Med 342:1902-1904.
11. Angell M. 2002. Is academic medicine for sale? N Engl J Med 342:1516-1518.
12. Appel L J. 2002. The verdict from ALLHAT: thiazide diuretics are the preferred initial therapy for hypertension. JAMA 288: 3039-3042.
13. Arnold FH. 1998. Design by directed evolution. Acct Chem Res 31:125-131.
14. Baker DW, Sudano JL, Albert JM, Borawski EA, Dor A. 2001. Lack of health insurance and decline in overall health in late middle age. N Engl J Med 345:1106-1112.
15. Barton JH. 2000. Reforming the patent system. Science 287: 1933-1934.
16. Beachy RN. 2003. IP policies and serving the public. Science 299:473.
17. Bernardelli P, Gaudilliere B, Vergbe F. 2002. To market, to market: 2001. Ann Rep Med Chem 37:257-275.
18. Birchard K. 2001. September 11th. Scientists worldwide protest withdrawal of job offer at U. of Toronto. Chron Higher Education.
19. Birchard K. 2002. U. of Toronto settles dispute over academic freedom and company-sponsored research. Chron Higher Education Nov. 14.
20. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
21. Blake CRL. 2001. The price of knowledge. Matrix Feb:11.
22. Blumenstyk G. 2002. Value of university licenses on patents exceeded $1 billion in 2000, survey finds. Chron Higher Education March 5.
23. Bodenheimer T. 2000. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med 342:1539-1544.
24. Bohacek RS, McMartin C, Guida WC. 1996. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 16:3-50.
25. Bok DC. 2003. Universities in the market place: The commercialization of higher education. Princeton, NJ: Princeton University, Press.
26. Boston Consulting Group. 2001. A revolution in R&D: Part II. The impact of genomics. July www.bcg.com.
27. Bowe C. 2003. Industry looks to the Maine chance. Financial Times (April 16).
28. Boyd EA, Bero LA. 2000. Assessing faculty financial relationships with industry. A case study. JAMA, 284 2209-2214.
29. Bradford TC. 2002. Export your innovations and unlock shareholder value. Curr Drug Discov 55-57.
30. Bradsher K. 2002. Once a close economic rival of China, India falls behind. NY Times (Nov 29) www.nytimes.com
31. Breinbauer R, Vetter IR, Waldmann H. 2002. From protein domains to drug candidates: natural products as guiding principles in the design and synthesis of compound libraries. Angewandte Chem Int. Ed 41:2878-2890.
32. Brenner S. 2001. Quoted in Davies K, After the genome: DNA and human disease. Cell 104:465-467.
33. Broder JM. 2002. Problem of lost health benefits is reaching into the middle class. NY Times Nov 25 www.nytimes.com
34. Broder S, Venter JC. 2000. Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. Ann Rev Pharmacol Toxicol 40:97-132.
35. Brown JR. 2000. Privatizing the university: the new tragedy of the commons. Science 290:1701-1702.
36. Bunk S. 2003. The alpha project. Scientist Feb 14:24-26.
37. Burton TM, Lueck S. 2003. FDA sends letter on Canada drugs. Wall Street J (March 15).
38. Burhart MD. 2003. Metabolic engineering: a genetic toolbox for small molecule organic synthesis. Org Biomol Chem 1:1-4.
39. Butte A. 2002. The rise and analysis of microarray data. Nature Rev Drug Discov 1:951-960.
40. Cane DE, Walsh CT, Khosla C. 1998. Harnessing the biosynthetic code: combinations, permutations, and mutations. Science 282:63-68.
41. Canham LT, Saffie BS, Connor SE, Aston R. 2001. Silicon technology and pharmaceutics. Drug Discov World Winter:56-63.
42. Capdeville R, Buchdunger E, Zimmerman J, Matter A. 2002. Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev Drug Discov 1:493-502.
43. Carmeliet P, Conway EM. 2001. Growing better blood vessels. Nature Biotech 19:1019-1020.
44. Carroll P, Fitzgerald K. 2003. Model organisms in drug discovery. New York: John Wiley & Sons.
45. Caulfield B. 2002. San Francisco Chronicle, Sept. 23. Scholars to debate the wisdom of continuing to patent genes. sfgate.com/cgi-bin/article.cgi?file=/c/a/2002/09/23/BU172513.DTL&type= printable
46. Center for Drug Evaluation and Research (CDER). 2001. CDER report to the nation: 2001. www.fda.gov/cder/reports/rtn/2001/rtn2001-1.htm
47. de Chadarevian S. 2002. Designs for life. Molecular biology after World War II. New York: Cambridge University Press.
48. Chanda SK, Caldwell HS. 2003. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today Feb:168-174.
49. Chartrand HG. 1989. University research in the information economy: a clash of cultures. www.culturaleconomics.atfreeweb.com/university.htm
50. Check E. 2002. Regulators split on gene therapy as patient shows signs of cancer. Nature 419:545-546.
51. Cho MK, Shohara R, Schissel A, Rennie D. 2000. Policies on faculty conflicts of interest at US universities. JAMA 284: 2203-2208.
52. Class S. 2002. Pharma overview. Chem Eng News Dec:39-47. http://pubs.acs.org/CEN
53. CMR International. 2001. New molecular entities (NMEs) first launched in 1991-2000. www.cmr.org/factoweek/factofweekOld/091001.html.
54. Coleman RA. 2003. Of mouse and man: what is the value of the mouse in predicting gene expression in humans? Drug Discov Today 8:233-235.
55. Commission on Intellectual Property Rights (CIPR). 2002. London, September. www.iprcommission.org
56. Commission on Macroeconomics and Health. 2001. Investing in health for economic development. Geneva, Switzerland: World Health Organization. Chair, Jeffrey D. Sachs. www3.who.int/whosis/menu.cfm?.path=whosis,cmh&language=english.
57. Cook G. 2002. Oncomouse breeds controversy. Cancer researchers at odds with du Pont over fees for patents. Boston Globe June 3. www.bostonglobe.com
58. Cooper RS, Kennelly JF, Durazo-Arvizu R, Oh HJ, Kaplan G, Lynch J. 2001. Relation between premature mortality and socioeconomic factors in black and white populations of US metropolitan areas. Pub Health Rep 116:464-473.
59. CorpWatch India. 2002. Intellectual property rights impose costs on most developing countries. Sept 12. www.corpwatch.india.org.
60. Couzin J. 2002. Smart weapons prove tough to design. Science 298:522-525.
61. Daniels N, Kennedy B, Kawahi I. 2000. Is inequality bad for our health? Boston: Beacon Press.
62. Datamonitor. 2002. Big pharma: tightening the marketer's purse strings. www.datamonitor.com. See also M. Peterson, Less return in Marketing of Medicines, a study says. NY Times Dec. 12 www.newyorktimes.com
63. Datamonitor. 2002. Big pharma: tightening the marketer's purse strings. www.datamonitor.com. See also M. Peterson, Less return in Marketing of Medicines, a study says. NY Times Dec. 12 www.newyorktimes.com
64. Davidson R, Gwatkin R, Guillot M. 2000. The burden of disease among the global poor: current situation, future trends and implications for strategy. Washington, DC: World Bank.
65. Davidov EJ, Hollan JM, Marple EW, Naylor S. 2003. Advancing drug discovery through systems biology. Drug Discov Today 8:175-183.
66. Davis K, Schoen C, Schoenbaum SC. 2000. A 2020 vision for American health care. Arch Int Med 160:3357-3362.
67. Debouck C, Metcalf B. 2000. The impact of genomics on drug discovery. Ann Rev Pharmacol Toxicol 40:193-222.
68. Delamarter J, Fumero S. 2002. Today's alliances for tomorrow's medicines. Drug Discov World Fall:9-14.
69. Desai MA, Kapur D, McHale J. 2001. The fiscal impact of the brain drain: Indian emigration. Presented at the Third Annual NBER-NCAER conference on Dec. 17/18. www.people.hbs.edu/mdesai/pubs.html
70. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. 1995. Cost of innovation in the pharmaceutical industry. J Health Econ 10: 107-142.
71. DiMasi, JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185.
72. Drews J. 2000. Drug discovery: a historical perspective. Science 287:1960-1964.
73. Drexler KE. 1994. Molecular nanomachines: physical principles and implementation strategies. Ann Rev Biophys Bioeng 23:377-405.
74. Drugs for Neglected Diseases. 2001. Fatal Imbalance. The crisis in research and development for drugs for neglected diseases. Medecins sans Frontieres. www.msf.org.
75. Dylan B. 1985. Simple twist of fate. In: Bob Dylan Lyrics 1962-1985. New York: Knopf.
76. The Economist. 1999. Drug-induced seizures. Drug mergers are all the rage; but few make much sense. Nov. 11.
77. The Economist. 2001. Protection racket. Brand-name drug makers are going to great lengths to spin out their patents. May 17.
78. The Economist. 2002a. Mercky prospects. Why are drug companies finding it so difficult to come up with new blockbusters? July 11.
79. The Economist. 2002b. With all thy getting, get understanding. Jan. 3.
80. The Economist. 2002c. Innovation's golden goose. Dec:3-30 (Technol Q).
81. The Economist. 2003a. Pushing pills. Marketing drugs to doctors is turning into a tricky business. Feb. 13.
82. The Economist. 2003b. The quest for the protein chip. March 13.
83. The Economist. 2003c. Exotic pursuits. Drug firms are starting to tackle tropical diseases. Jan 30.
84. The Economist. 2003d. The other war. George Bush's pledge of more money to fight AIDS should be welcomed. Jan 30.
85. Eisenberg ES. 2003. Patent swords and shields. Science 299: 1018-1019.
86. Evans BE, Ruttle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lindell GF, Veber DF, Anderson PS, Chang RSL, Lotti VJ, Cerino DJ, Chen TB, Kling PJ, Kinkel KA, Springer JP, Hirshfield J. 1988. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 31:2235-2241.
87. Feachem R. 2001. Forum 5. Geneva, Switzerland: Global Forum Health Research, October.
88. Fenske C, Palm GJ, Hinrichs W. 2003. How unique is the genetic code? Angew Chem Int Ed 42:606-610.
89. Feynman RA. 1959. There's plenty of room at the bottom. Reprinted in Science 1991;254:1300-1301.
90. Flattmann GJ, Kaplan JM. 2002. Licensing research tool patents. Nature Biotechnol 20:945-947.
91. Fogarty M. 2002. The reality of targeted therapies. Scientist Oct 14:35-36.
92. Frank RG. 2003. New estimates of drug development costs. J Health Econ 22:325-330.
93. Frantz S, Smith A. 2003. New drug approvals for 2002. Nature Rev Drug Discov 2:95-96.
94. Freemantle M. 2002. Amplification of the fittest. Chem Eng News Sept 2:31-33.
95. Freitas RA Jr. 2000. Say "Ah!" Sciences 40:26-31.
96. Fuchs VR. 2002. What's ahead for health insurance in the United States? N Engl J Med 346:1822-1824
97. Galiani S, Gertler P, Schargodsky E. 2003. Water for life: the impact of privatization of water services on child mortality. http://faculty.haas.berkeley.edu/gertler/
98. Gallup JL, Sachs JD. 2001. The economic impact of malaria. Geneva: World Health Organization, Commission on Macroeconomics and Health. Paper no. WG1:10.
99. Gelijns AC. Their SO. 2002. Medical innovation and institutional interdependence. JAMA 287:72-77.
100. Genetic Engineering News. 2003. Molecular Millionaires April 1:23, no. 7.
101. Gershell LJ, Atkins JH. 2003. A brief history of novel drug discovery technologies. Nature Rev Drug Discov 2:321-327.
102. Global Alliance for TB Drug Development. 2001. Drug development costs. www.tballiance.org
103. Global Forum for Health Research. 2002. The 10/90 report on health research 2001-2002. Geneva: World Health Organization. www.globalforumhealth.org
104. Gogoris A, Ancona P. 2001. Research tool patents: tips for facing a "pay up now or litigate" ultimatum. Nature Biotechnol 19: 1075-1077.
105. M. Goho. 2003. Made to order. MIT Technol Rev April:51-57.
106. Goldberg M. 2002. The zealots behind President Bush's U. N. family planning sellout. Salon June 13. www.salon.xom/news/feature/2002/06/13/unfpa/print.html.
107. Goode E. 2002. The heavy cost of chronic stress. NY Times Dec 17.
108. Goodman L. 2002. Celebrity pill pushers. Salon July 11. www.salon.com/mwt/feature/2002/07/11/celebrity_drugs/print.html
109. Goozner M. 2000. The price isn't right. Am Prospect Sept 11(20):25-29.
110. Green RM. 2001. The human embryo research debates. Bioethics in the vortex of controversy. New York: Oxford University Press.
111. Grusky S. 2002. The IMF, the World Bank and the global water companies: A shared agenda. www.citizen.org/documents/sharedagenda.pdf
112. Gunter C, Dhand R. 2002. Human biology by proxy. Nature 420:509. (The subsequent articles in this issue of Nature detail the mouse genome.)
113. Harris T. 2000. Genetics, genomics and drug discovery. Med Res Rev 20:203-211.
114. Heller MA, Eisenberg RS. 1998. Can patents deter innovation? The anticommons in biomedical research. Science 280:698-701.
115. Heller DJ. 2003. Canada rules that transgenic animals are nonpatentable, Genet Eng News March 23:6.
116. Henry D, Lexchin J. 2002. The pharmaceutical industry as a medicines provider. Lancet 360:1590-1596.
117. Hensley S. 2003. Concern is growing over spike in prices of prescription drugs. Wall Street J April 16.
118. Hertzman C. 2001. Health and human society. Am Scientist Nov/Dec:538-545.
119. Hoffmann S. 1992. Artificial replication systems. Angewandte Chem Int Ed 31:1013-1016.
120. Hopkins AL, Groom CR. 2002. The druggable genome. Nature Rev Drug Discov 1:727-730.
121. Horowitz DJ. 2003. Warning letter to Harry Lee Jones. March 21. www.fda.gov/foi/warning_letters/g3888d.htm
122. Horrobin DF. 2000. Innovation in the pharmaceutical industry. J R Soc Med 93:341-345.
123. Horrobin DF. 2003. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nature Rev Drug Discov 2:151-154.
124. Howard AD, McCallister G, Feighner SD, Liu Q, Nargund RP, Van der Ploeg LHT, Patchett AA. 2001. Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol Sci 22:132-139.
125. Huddlestone T. 1956. Naught for your comfort. New York: Doubleday.
126. Hurley LH. 1987. Molecular biology and medicinal chemistry. J Med Chem 30:7A-8A.
127. Issac R, Ham Y-H, Chmielewski J. 2001. The design of self-replicating helical peptides. Curr Opin Struct Biol 11:458-463.
128. Jacobs S. 2002. An oral drug for leishmaniasis. N Engl J Med 347:1737-1738.
129. Jander T. 2003. Prescription drug imports. Wall Street J March 31 (Letter to Editor).
130. Jaroff L. 2003. It's time to rethink ephedra regulation. Time March 5.
131. Joint National Committee Six. 1997. The Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Int Med 157:2413-2446.
132. Jones E. 2003. Toil and trouble in the pharma industry. Curr Drug Discov January:43-45.
133. Joost P, Methner A. 2002. Phylogenetic analysis of 227 human G-protein-coupled reeceptors as a tool for the prediction of orphan receptor ligands, Genome Biology. At http://genomebiologfy.com/2002/3/11/research/0063.1
134. Joseph T. 2002. The BW Roundtable. Five reasons for cheer on pharma nd one for concern. Businessworld October 21:33-42.
135. Joshi HN. 2003. Analysis of the Indian Pharmaceutical Industry. With emphasis on opportunities in 2005. Pharmaceut Technol January:74-94.
136. Joyce GF 1992. Directed molecular evolution. Sci Am December:90-97.
137. Joynt J, Shuchart C. 2003. Portal Justice. The demography of the death penalty. Atlantic Monthly March:40-41.
138. Kamath RS, Fraser AG, Dong Y, Poulin G, Gotta M, Kanapin A, Le Bot N, Moreno S, Sohrmann M, Welchman DP Zipperlen P, Ahringer J. 2003. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421:231-237.
139. Kaplan GA. 2000. Economic policy is health policy. In: Auerbach JA, Krimgold BK, editors. Income, socioeconomic status, and health: exploring the relationships. Washington, DC: National Policy Association Academy for Health Services and Health Policy. p 137-148.
140. Kauffman SA. 1996. Self-replication: even peptides do it. Nature 382:496-497.
141. Khosla C, Gokhale RS, Jacobsen JR, Cane DE. 1999. Tolerance and specificity of poyketide synthases. Ann Rev Biochem 68: 219-253.
142. Klekota B, Miller BL. 1999. Dynamic diversity and small molecule evolution: a new paradigm for ligand identification. Trends Biotechnol 17:205-210.
143. Kliewer SA, Lehmann JM, Willson TM. 1999. Orphan nuclear receptors: shifting endocrinology into reverse. Science 284: 757-760.
144. Kolb HC, Finn MG, Sharpless KB. 2001. Click chemistry: diverse chemical function from a few good reactions. Angewandte Chem Int Ed 40:2004-2021.
145. Krugman P. For richer. NY Times (Magazine) Oct. 20.
146. Lancet. 2001. Patent protection versus public health. 358:1563.
147. Lancet. 2002. An innovative challenge to the pharmaceutical industry. 360:1341.
148. Lanjouw JO, Schankerman M. 2001. Enforcing intellectual property rights. National Bureau of Economic Research, Working paper 8656, December. www.nber.org/papers/w8656
149. Lee DH, Granja JR, Martinez JA, Severin K, Ghadiri MR. 1996. A self-replicating system. Nature 382:525-528 (www.scripps.edu/Chem/ghadiri/html/selfrepli.html)
150. Lehn JM. 1999. Dynamic combinatorial chemistry and virtual combinatorial libraries. Chem Eur J 5:2455-2463.
151. Leonard DS, Hill ADK, Kelly L, Dijkstra B, McDermott E, O'Higgins, NJ. 2002. Anti-human epidermal growth factor receptor 2 monoclonal antibody for breast cancer. Br J Surg 89:262-271.
152. Lessig L. 2001. The future of ideas. The fate of the commons in a connected world. New York: Random House.
153. Lewis WG, Green LG, Grynszpan F, Radic Z, Caelier PR, Taylor P, Finn MG, Shaepless KB. 2002. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angewandte Chem Int Ed 41:1053-1054.
154. Lichtenberg FR. 2002. The effect of new drugs on longevity and quality of life. LDI Research Seminar Series. Nov. 15. www.upenn.edu/ldi/lichtenberg.html
155. Loff A. 2002. No agreement reached in talks on access to cheap drugs. Lancet 360:1951.
156. Longman PJ. 2003. The health of nations. Wash Monthly April: 16-23.
157. Lu PY, Xie FY, Scaria P, Woodle MC. 2003. From correlation to causation to control: utilizing preclinical disease models to improve target discovery. Preclinica 31:31-42, March/April. www.preclinica.com
158. Ma Z, Taylor J-S. 2000. Nucleic acid-triggered catalytic drug release. Proc Natl Acad Sci USA 97:11159-11163.
159. MacKenzie M. 2001. Protection racket. New Scientist July 21: 18-20.
160. Malakoff A. 2003. Universities ask supreme court to reverse patent ruling. Science 299:26-27.
161. Marshall E. 2001. Universities, NIH hear the price isn't right on essential drugs. Science 292:614-615.
162. Marshall E. 2002. DuPont ups ante on use of Harvard's oncomouse. Science 296:1212-1213.
163. Martens P, Hall L. 2000. Malaria on the move: human population movement and malaria transmission. Emerg Infect Dis 6:7-13.
164. McKibben W. 2003. Enough. Staying human in an engineered age. New York: Time Books.
165. McIlroy A. 2001. Drug research walks thin line. Globe Mail Jan 1-4.
166. McLuhan M. 2003. Cited in www.marshall.mcluhan.com
167. McClure L. 2002. Bush's drive for global abstinence. Salon Dec 19. www.salon.com/news/feature/2002/12/19/population/print.html.
168. Mehl RA, Anderson JC, Santoro SW, Wang L, Martin AB, King DS, Horn DM, Schultz PG. 2003. Generation of a bacterium with a 21 amino acid genetic code. J Am Chem Soc 125:935-939.
169. Miller H. 2002. As biotech turns 20. Nature Rev Drug Discov 2:1007-1008.
170. Miller KW, Triggle DJ. 2002. Doctoral education: another tragedy of the commons? Am J Pharmaceut Educ 60:287-294.
171. Miska A. 2003. Biotech's twentieth birthday blues. Nature Rev Drug Discov 2:231-233.
172. Mitka M. 2003. Survey suggesting that prescription drug ads help public is met with skepticism. JAMA 289:827-828.
173. Moynihan R, Heath I, Henry D. 2002. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324: 886-890.
174. Mullin R. 2003. Biotech vies for position. C & E News Jan 27:27-44.
175. Nagl SB. 2002. Computational functional assignment for potential drug targets: from single genes to cellular systems. Curr Drug Targets 3:387-399.
176. Nathan DG, Weatherall DJ. 2002. Academic freedom in clinical research. N Engl J Med 347:1368-1371.
177. National Intelligence Council. 2002. The Next Wave of HIV/AIDS: Nigeria, Ethiopia, Russia, India, and China. September. www.fas.org/irp/nic/hiv-aids.html
178. Nature. 2002. Special feature. Plasmodium genomics 419:489-542.
179. New Scientist. 2002. The people vs. patents. July 13:3.
180. Newman N. 2002. Net-Loss. Internet prophets: private profits and the cost to community. University Park, PA: Penn State University Press.
181. NICHM Foundation. National Institute for Health Care Management Research and Educational Foundation. 2000. Prescription Drugs and Mass Media Advertising, September. www.nihcmorg
182. NICHM Foundation, National Institute for Health Care Management Research and Educational Foundation. 2002. Changing patterns of pharmaceutical innovation. May www.nihcm.org
183. Nolan PM. 2000. Generation of mouse mutants as a tool for functional genomics. Pharmacogenomics 1:243-255.
184. Nuffield Council on Bioethics. 2002. The ethics of Patenting DNA. A discussion paper. www.nuffieldbioethics.org.
185. Olivera BM, Hillyard DR, Marsh M, Yoshikami D. 1995. Combinatorial peptide libraries in drug design: lessons from venomous cone snails. Trends Biotech 13:422-426.
186. Otto S, Furlan RLE, Sanders JKM. 2002. Dynamic combinatorial chemistry. Drug Discov Today 7:117-125.
187. Pacotti S. 2003. Are we doomed yet? Salon March 31. www.salon.com/tech/feature/2003/03/31/knowledge/print.html
188. Patchett AA, Nargund RO. 2000. Privileged structures: an update. Ann Rep Med. Chem 35:289-298.
189. Paul N, Joyce GF. 2002. A self-replicating ligase ribozyme. Proc Natl Acad Sci USA 99:12733-12740.
190. Peakman T, Franks S, White C, Beggs M. 2003. Delivering the power of discovery in large pharmaceutical organizations. Drug Discov Today March:203-211.
191. Pearson H. 2002. Surviving a knockout blow. Nature 415:8-9.
192. Pecorino P. 2003. Should the U.S. allow prescription drug reimports from Canada? J Health Econ 21:699-708.
193. Petersen M. 2002. Madison avenue plays growing role in drug research. NY Times Nov 22. www.nytimes.com/2002/11/22/ business/22DRUG.html?pageewanted=print&position=
194. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. 2002. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev Drug Discov 1:683-695.
195. Powell KA, Ramer SW, del Cardayre SB, Stemmer WPC, Tobin MB, Longchamp PF, Huisman GW. 201. Angewandte Chem Int Ed 40:3948-3959.
196. Pratt EJ. 1997. Intellectual property. www.pfizer.com/pfizerinc/ policy/intellectualpropfrm.html.
197. Prendergast G. 2001. Knockout drug screens. Nature Biotechnol 19:919-920.
198. Public Citizen. 2001a. Water for all. www.citizen.org/cmep/water/
199. Public Citizen. 2001b. RRx R&D myths: the case against the drug industry's R&D "scare card". July www.citizen.org
200. Public Citizen. 2001c. Critique of the DiMasi/Tufts methodology and other key prescription Drug R&D issues. Dec. www.citizen.org/print_article.cfm?ID=6532
201. Rai AK, Eisenberg RS. 2003. Bayh-Dole reform and the progress of biomedicine Am Scientist Jan-Feb:52-59.
202. Ramachandra M, Rahman A, Zon A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demrs GW, Engler H, Johnson D, Shabram P. 2001. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nature Biotechnol 19:1035-1041.
203. Raven PH. 2002. Science, sustainability and the human prospect. Science 297:954-958.
204. Rees M. 1999. Just six numbers. London: Weidenfeld and Nicolson.
205. Robertson DW, Willy PJ, Heyman RA, Maugelsdorf DJ. 1997. Nuclear orphan receptors: scientific progress and therapeutic opportunities. Ann Rep Med Chem 32:251-260.
206. Rosenberg T. 2001. Patent laws are malleable. Patients are educable. Drug companies are vincible. The world's AIDS crisis is solvable. NY Times (Magazine) Jan. 28.
207. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. 2002. Promotion of prescription drugs to consumers. N Engl J Med 346:498-505.
208. Rouhi AM. 2002a. Generic tide is rising. C & E News Sept 23:37-51.
209. Rouhi AM. 2002b. Beyond Hatch-Waxman. Legislative action seeks to close loopholes in U.S. law that delay entry of generics into the market. C & E. News Sept 23:53-65.
210. Rouhi AM. 2002c. Paying attention to unmet needs. Chem Eng News Sept 23:67-76.
211. Rudolph U, Mohler H. 1999. Genetically modified animals in pharmacological research: future trends. Eur J Pharmacol 375:327-337.
212. Russ A, Stumm G, Augustin M, Sedlmeier R, Wattler S, Nehls M. 2002. Random mutagenesis in the mouse as tool in drug discovery. Drug Discov Today 7:1175-1183.
213. Sachs J. 2002a. The essential ingredient. New Scientist Aug 17: 52-55.
214. Sachs J. 2002b. Earth's institute Jeffrey Sachs sees location as factor in poverty plaguing some nations. American Association for Advancement of Science, Press release Dec 5. www.aaas.org/news/releases/2002/1205sachs.shtml
215. Salt Lake Tribune. 2003. Hatch and ephedra. March 2. www.sltrib. com/2003/Mar/03022003/Opinion/Opinion.asp?display=print
216. Sanders B (U.S. Congressman). 2003. Americans must have access to cheaper Canadian drugs. Buffalo News March 16. http://bernie.house.gov/documents/opeds/20030318085012.asp?print
217. Sarmiento A. 1999. The Gallie Lecture, Royal College of Physicians and Surgeons Annual meeting. He who pays the piper calls the tune. www.mednet.ca/html/info-spec9909.htm
218. Schnell MJ, Johnson JE, Buonocore L, Rose JK. 1997. Construction of a novel virus that targets HIV-1 infected cells and controls HIV-1 infection. Cell 90:849-853.
219. Science 2002. Special feature. Taking a bite out of the malaria mosquito. 298:77-218.
220. Scientific American. 2001. Special Issue. Nanotech. The science of the small gets down to business. September.
221. Shanghvi D. 2003. Indian pharma companies: Bridging the resource gap. Pharmaceut News (in press).
222. Shirvill J. 2002. Patenting DNA: a rare exception or the norm? Curr Drug Discov Sept:46-49.
223. Shulman S. 2001. PB&J patent punch-up. Technol Rev May:37.
224. Singer K. 2001. In pursuit of patents. Matrix February: 32-38.
225. Smith C. 2003. Hitting the target. Nature 422:341-347.
226. Smith RA. 2001. Nanotechnology gains momentum. Mod Drug Discov April:33-36.
227. Specter M. 2001. India's plague. New Yorker Dec 17:74-85.
228. Stiglitz J. 2002. Globalization and its discontents. New York: W. W. Norton.
229. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. 2002. Oral miltefisone for Indian visceral leishmaniasis. N Engl J Med 347:1739-1746.
230. Szczebara FM, Chandelier C, Villeret C, Masurel A, Bourot S, Duport C, Blanchard S, Grosillier A, Testet E, Costaglio P, Cauet G, Degryse E, Balabuena D, Winter J, Aschetter T, Spagnoli R, Pompon D, Dumas B. 2003. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Nature Biotechnology 21:143-149.
231. Takacs L, Vazquez-Abad M.-D, Elliott E. A. 2001. Therapeutic monoclonal antibodies: history, facts and trends. Ann Rep Med Chem 36:237-246.
232. Tan TS, Foley MA, Shair MD, Schreiber SL 1998. Stereoselective synthesis of over two million compounds having structural features both reminiscent of natural products and compatible with miniaturized cell-based assays. J Am Chem Soc 120: 8565-8566.
233. Thompson JD. 2002. Application of antisense and siRNAs during preclinical drug development. Drug Discov Today 7:912-917.
234. Thompson RB. 2001. Foundations for blockbuster drugs in federally sponsored research. FASEB J 15:1671-1676.
235. Tjivikua T, Ballester P, Rebek R. 1990. A self-replicating system. J Am Chem Soc 112:1249-1250.
236. Todd A. 1956. In: Todd A, editor. Perspectives in organic chemistry. New York: Interscience. p 245.
237. Tremblay JF. 2002. Speeding up drug discovery. South Indian entrepreneurs offer contract research services to global pharma. C&E News June 3:13-20.
238. Triggle DJ 1996. Medicinal chemistry. In: Encyclopedia of molecular cell biology and molecular medicine. New York: R.A. Meyers, Wiley-VCH.
239. Triggle DJ. 1999. Pharmaceutical sciences in the next millennium. Ann Pharmacother 33:241-246.
240. Triggle DJ. 2003a. Everybody must get cloned. Free Inquiry 23: 32-33.
241. Triggle DJ. 2003b. The 1,4-dihydropyridine nucleus: a pharmacophoric template. Part 1. Actions at ion channels. MiniRev Med Chem 3:217-225.
242. Tufts Center for the Study of Drug Development. 2001. htttp:// csdd.tufts.edu. Nov. 30. The press release may be accessed at csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=6 2001.
243. Tyers M, Mann M. 2003. From proteomics to genomics. Nature 422:193-198.
244. United Nations Population Division. 2003. www.un.org/esa/population/unpop
245. United Nations Population Fund (UNFPA). 2002. State of World Population 2002. www.unfpa.org
246. Vasserot AP, Dickinson CD, Tang Y, Huse WD, Manchester KS, Watkins JD. 2003. Optimization of protein therapeutics by directed evolution. Drug Discov Today 8:118-126.
247. Vogelstein B, Kinzler KW. 2001. Achilles' heel of cancer? Nature 412:865-866.
248. Wallis K, Richmond M, Patchett T. 2000. The impact of genomics on the pharmaceutical industry. Price, Waterhouse, Coopers www.pwcglobal.com.
249. Watson JD, Crick FHC. 1953. A structure for deoxyribose nucleic acid. Nature 171:737-738.
250. Weber MA. 2003. The ALLHAT report: a case of information and misinformation. J Clin Hypertens 5:9-13.
251. Weller CE, Hersh A. 2002. Free markets and poverty. Am Prospect 13 January 1-14.
252. Whitty CJM, Rowland M, Sanderson F, Mutabigwa TK. 2002. Malaria BMJ 325:1221-1224.
253. Wiley RA, Rich DH. 1993. Peptidomimetics derived from natural products. Med Res Rev 13:327-384.
254. Wilkinson RG. 2000. Mind the gap. Hierarchies, health and human evolution. New Haven: Yale University Press.
255. Williamson AR. 2001. Gene patents. Socially acceptable monopolies or an unnecessary hindrance to research? Trends Genet 17: 670-673.
256. Willis RC. 2002. May. Infringement for the public good. Mod Drug Discov May:41-45.
257. Wilson EK. 1998. Go forth and multiply. Chem Eng News Dec 7:40-44.
258. Wilson AO. 2002. The future of life. New York: Knopf.
259. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLT, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. 2003. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583-592.
260. Wintner EA, Conn MM, Rebek J Jr. 1994. Studies in molecular self-replication. Acct Chem Res 27:198-203.
261. Wirth DF. 1999. Malaria: A third world disease in need of first world drug discovery. Ann Rep Med Chem 34:349-358.
262. Wise A, Gearing K, Rees S. 2002. Target validation of G-protein coupled receptors. Drug Discov Today 7:235-246.
263. Wolfson M, Kaplan G, Lynch J, Ross, N, Backlund E. 1999. Relation between income inequality and mortality: empirical demonstration. Br Med J 319:953-957.
264. World Health Organization. 2000. The World Health Report, 1999. Burden of disease by cause, sex and mortality stratum in WHO regions. Geneva: WHO.
265. Yamey G. 2002. The world's most neglected diseases. Br Med J 325:176-177.
266. Zacharias N, Farias S, 2002. Patents and the Indian pharmaceutical industry. www.wmrc.com/businessbriefing/pdf/pharmatech2002/ book/zacharias.pdf
267. Zambrowicz BP, Sands AT. 2003. Knockouts model the 100-best-selling drugs: will they likely model the next 100? Nature Drug Discov Rev 2:38-51.
268. Zehr L. 2003. Mail order suppliers under gun. Globe and Mail Feb 8. www.workopolis.com/servlet/Content/qprinter/20030208/RGLAX
269. Zhu H, Bunn HF. 2001. How do cells sense oxygen? Science 292:449-451.
270. Zimmer B, 2003. Tinker, Tailor: Can Venter stitch together a genome from scratch? Science 299:1006-1007.
271. Zumeta W, Raveling JS. 2002. The best and brightest for science: Is there a problem here? Commission on Professionals in Science and Technology, Washington, DC www.cpst.org